ADAM12 as a marker of trisomy 18 in the first and second trimester of pregnancy

References

• Snijders R J, Sebire N J, Nicolaides K H. Maternal age and gestational age-specific risks for chromosome defects. Fetal Diagn Ther 1995; 10: 356–367
   PubMed Web of Science ®Google Scholar
• Sherod C, Sebire N J, Soares W, Snijders R JM, Nicolaides K H. Prenatal diagnosis of trisomy 18 at the 10–14 week ultrasound scan. Ultrasound Obstet Gynecol 1997; 10: 387–390
   PubMed Web of Science ®Google Scholar
• Snijders R J, Brizot M L, Faria M, Nicolaides K H. Fetal exomphalos at 11 to 14 weeks of gestation. J Ultrasound Med 1995; 14: 569–574
   PubMed Web of Science ®Google Scholar
• Spencer K, Macri J N, Aitken D A, Connor J M. Free β-hCG as first trimester marker for fetal trisomy. Lancet 1992; 339: 1480
   PubMedGoogle Scholar
• Brambati B, Lanzani A, Tului L. Ultrasound and biochemical assessment of first trimester pregnancy. The embryo: Normal and abnormal development and growth, M Chapman, J G Grudzinskas, T Chard. Springer-Verlag, New York 1991; 181–194
   Google Scholar
• Tul N, Spencer K, Noble P, Chan C, Nicolaides K. Screening for trisomy 18 by fetal nuchal translucency and maternal serum free β-hCG and PAPP-A at 10–14 weeks of gestation. Prenat Diagn 1999; 19: 1035–1042
   PubMed Web of Science ®Google Scholar
• Nicolaides K H, Spencer K, Avgidou K, Faiola S, Falcon O. Multicenter study of first trimester screening for trisomy 21 in 75,821 pregnancies: Results and estimation of the potential impact of individual risk-orientated two-stage first trimester screening. Ultrasound Obstet Gynecol 2005; 25: 221–226
   PubMed Web of Science ®Google Scholar
• Spencer K, Nicolaides K H. A first trimester trisomy13/trisomy18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free β-hCG and PAPP-A. Prenat Diagn 2002; 22: 877–879
   PubMed Web of Science ®Google Scholar
• Papageorghiou A T, Avgidou K, Spencer K, Nix B, Nicolaides K H. Sonographic screening for trisomy 13 at 11 to 13 + 6 weeks of gestation. Am J Obstet Gynecol 2006; 194: 397–401
   PubMedGoogle Scholar
• Liao A W, Snijders R, Geerts L, Spencer K, Nicolaides K H. Fetal heart rate in chromosomally abnormal fetuses. Ultrasound Obstet Gynecol 2000; 16: 610–613
   PubMed Web of Science ®Google Scholar
• Gilpin B J, Loechel F, Mattei M G, Engvall E, Albrechtsen R, Wewer U M. A novel, secreted form of human ADAM 12 (meltrin alpha) provokes myogenesis in vivo. J Biol Chem 1998; 273: 157–166
   PubMed Web of Science ®Google Scholar
• Shi Z, Xu W, Loechel F, Wewer U M, Murphy L J. ADAM 12, a disintegrin metalloprotease, interacts with insulin-like growth factor-binding protein-3. J Biol Chem 2000; 275: 18574–18580
   PubMed Web of Science ®Google Scholar
• Loechel F, Fox J W, Murphy G, Albrechtsen R, Wewer U M. ADAM 12 cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. Biochem Biophys Res Commun 2000; 278: 511–515
   PubMed Web of Science ®Google Scholar
• Rosenfeld R G, Roberts C T. The IGF system. Molecular biology, physiology, and clinical applications. Humana Press, Totowa, New JerseyUSA 1999; 1–787
   Google Scholar
• Laigaard J, Sorensen T, Frohlich C, Pedersen B N, Christiansen M, Schiott K, Uldbjerg N, Albrechtsen R, Clausen H V, Ottesen B, Wewer U M. ADAM12: A novel first-trimester maternal serum marker for Down syndrome. Prenat Diagn 2003; 23: 1086–1091
   PubMed Web of Science ®Google Scholar
• Laigaard J, Cuckle H, Wewer U M, Christiansen M. Maternal serum ADAM12 levels in Down's and Edwards' syndrome pregnancies at 9–12 weeks gestation. Prenat Diagn 2006; 26: 689–691
   PubMed Web of Science ®Google Scholar
• Laigaard J, Christiansen M, Frohlich C, Pedersen B N, Ottesen B, Wewer U M. The level of ADAM12 in maternal serum is an early first-trimester marker of fetal trisomy 18. Prenat Diagn 2005; 25: 45–46
   PubMed Web of Science ®Google Scholar
• Laigaard J, Sorensen T, Placing S, Holck P, Frohlich C, Wojdemann K R, Sundberg K, Shalmi A C, Tabor A, Norgaard-Pedersen B, et al. Reduction of the disintegrin and metalloprotease ADAM12 in preeclampsia. Obstet Gynecol 2005; 106: 144–149
   PubMed Web of Science ®Google Scholar
• Laigaard J, Spencer K, Christiansen M, Cowans N J, Larsen S O, Pedersen B N, Wewer U M. ADAM 12 as a first trimester maternal serum marker in screening for Down syndrome. Prenat Diagn 2006; 26: 973–979
   PubMed Web of Science ®Google Scholar
• Christiansen M, Spencer K, Laigaard J, Cowans N J, Larsen S O, Wewer U M. ADAM12 as a second trimester maternal serum marker in screening for Down's syndrome. Prenat Diagn 2007; 27: 611–615
   PubMed Web of Science ®Google Scholar
• Spencer K, Spencer C E, Power M, Dawson C, Nicolaides K H. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: A review of three years prospective experience. BJOG 2003; 110: 281–286
   PubMed Web of Science ®Google Scholar
• Spencer K. Second trimester prenatal screening for Down's syndrome using alpha-fetoprotein and free beta hCG: A seven year review. BJOG 1999; 106: 1287–1293
   Google Scholar
• Spencer K, Souter V, Tul N, Snijders R, Nicolaides K H. A screening program for trisomy 21 at 10–14 weeks using fetal nuchal translucency, maternal serum free β-human chorionic gonadotropin and pregnancy associated plasma protein-A. Ultrasound Obstet Gynaecol 1999; 13: 231–237
   PubMed Web of Science ®Google Scholar
• Snijders R J, Noble P, Sebire N, Souka A, Nicolaides K H. UK multicentre project on assessment of risk for trisomy 21 by maternal age and fetal nuchal translucency thickness at 10–14 weeks of gestation. Lancet 1998; 18: 519–521
   Google Scholar
• Snijders R J, Sundberg K, Holzgreve W, Henry G, Nicolaides K H. Maternal age and gestation specific risk for trisomy 21. Ultrasound Obstet Gynaecol 1999; 13: 167–170
   PubMed Web of Science ®Google Scholar
• Ong C Y, Liao A W, Spencer K, Munim S, Nicolaides K H. First trimester maternal serum free β human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications. BJOG 2000; 107: 1265–1270
   PubMed Web of Science ®Google Scholar
• Spencer K, Bindra R, Nicolaides K H. Maternal weight correction of maternal serum PAPP-A and free β-hCG when screening for trisomy 21 in the first trimester of pregnancy. Prenat Diagn 2003; 23: 851–855
   PubMed Web of Science ®Google Scholar
• Nicolaides K H, Snijders R J, Cuckle H S. Correct estimation of parameters for ultrasound nuchal translucency screening. Prenat Diagn 1998; 18: 519–521
   PubMed Web of Science ®Google Scholar
• Royston P, Thompson S G. Model based screening by risk with application to Down's syndrome. Stats Med 1992; 11: 257–268
   PubMed Web of Science ®Google Scholar
• Office of National Statistics. Series FM1 No. 33. Birth statistics (2004). Stationery Office, London 2005
   Google Scholar
• Spencer K, Crossley J A, Aitken D A, Nix A BJ, Dunstan F DJ, Williams K. Temporal changes in maternal serum biochemical markers of trisomy 21 across the first and second trimester of pregnancy. Ann Clin Biochem 2002; 39: 567–576
   PubMed Web of Science ®Google Scholar
• Spencer K, Crossley J A, Aitken D A, Nix A B, Dunstan F D, Williams K. The effect of temporal variation in biochemical markers of trisomy 21 across the first and second trimester of pregnancy on the estimation of individual patient specific risks and detection rates for Down's syndrome. Ann Clin Biochem 2003; 40: 219–231
   PubMed Web of Science ®Google Scholar
• Lawrence J B, Oxvig C, Overgaard M T, Sottrup-Jensen L, Gleich G J, Hays L G, Yates J R, Conover C A. The insulin-like growth factor (IGF)-dependent binding protein-4-protease secreted by human fibroblasts is pregnancy associated plasma protein-A. Proc Natl Acad Sci U S A 1999; 96: 3149–3153
   PubMed Web of Science ®Google Scholar
• Spencer K, Crossley J A, Green K, Worthington D J, Brownbill K, Aitken D A. Second trimester levels of pregnancy associated plasma protein-A in cases of trisomy 18. Prenat Diagn 1999; 19: 1127–1134
   PubMedGoogle Scholar
• Muller F, Sault C, Lemay C, Roussl-Mizon N, Forestier F, Frendo J L. Second trimester two step trisomy 18 screening using maternal serum markers. Prenat Diagn 2002; 22: 605–608
   PubMedGoogle Scholar
• Smith G S, Stenhouse E J, Crossley J A, Aitken D A, Cameron A D, Connor J M. Early pregnancy levels of pregnancy associated plasma protein A and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J Clin Endocrinol Metab 2004; 87: 1762–1767
   Google Scholar
• Cowans N J, Spencer K. First trimester ADAM12 and PAPP-A as markers for intrauterine fetal growth restriction through their roles in the insulin-like growth factor system. Prenat Diagn 2007; 27: 264–271
   PubMed Web of Science ®Google Scholar
• Lamson G, Giudice L C, Cohen P, Liu F, Gargosky S, Muller H L, Oh Y, Wilson K F, Hintz R L, Rosenfeld R G. Proteolysis of IGFBP-3 may be a common regulatory mechanism of IGF action in vivo. Growth Regul 1993; 3: 91–95
   PubMedGoogle Scholar